Abstract
Sarcopenia, the progressive loss of muscle mass with age, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Since these age-related changes in skeletal muscle are largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostatis, and apoptosis, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. We and other researchers demonstrated that a disruption of Akt-mTOR and RhoA-SRF signaling but not Atrogin-1 or MuRF1 contributes to sarcopenia. In addition, sarcopenia seems to include a marked loss of fibers attributable to apoptosis. This review deals with molecular mechanisms of muscle atrophy and provides an update on current strategies (resistance training, myostatin inhibition, treatment with amino acids or testosterone, calorie restriction, etc) for counteracting this loss. Resistance training in combination with amino acid-containing nutrition would be the best candidate to attenuate, prevent, or ultimately reverse age-related muscle wasting and weakness.
Keywords: Sarcopenia, SRF, testosterone, myostatin, skeletal muscle
Current Aging Science
Title: Molecular Mechanisms in Aging and Current Strategies to Counteract Sarcopenia
Volume: 3 Issue: 2
Author(s): Kunihiro Sakuma and Akihiko Yamaguchi
Affiliation:
Keywords: Sarcopenia, SRF, testosterone, myostatin, skeletal muscle
Abstract: Sarcopenia, the progressive loss of muscle mass with age, is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Since these age-related changes in skeletal muscle are largely attributed to various molecular mediators affecting fiber size, mitochondrial homeostatis, and apoptosis, the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. We and other researchers demonstrated that a disruption of Akt-mTOR and RhoA-SRF signaling but not Atrogin-1 or MuRF1 contributes to sarcopenia. In addition, sarcopenia seems to include a marked loss of fibers attributable to apoptosis. This review deals with molecular mechanisms of muscle atrophy and provides an update on current strategies (resistance training, myostatin inhibition, treatment with amino acids or testosterone, calorie restriction, etc) for counteracting this loss. Resistance training in combination with amino acid-containing nutrition would be the best candidate to attenuate, prevent, or ultimately reverse age-related muscle wasting and weakness.
Export Options
About this article
Cite this article as:
Sakuma Kunihiro and Yamaguchi Akihiko, Molecular Mechanisms in Aging and Current Strategies to Counteract Sarcopenia, Current Aging Science 2010; 3 (2) . https://dx.doi.org/10.2174/1874609811003020090
DOI https://dx.doi.org/10.2174/1874609811003020090 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica
Current Neurovascular Research Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and Aggregation
Current Pharmaceutical Design Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Lentiviral Transgenesis - A Versatile Tool for Basic Research and Gene Therapy
Current Gene Therapy The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
CNS & Neurological Disorders - Drug Targets The AMP-Activated Protein Kinase: Role in Regulation of Skeletal Muscle Metabolism and Insulin Sensitivity
Mini-Reviews in Medicinal Chemistry Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Does Human Alpha-Synuclein Behave Like Prions?
CNS & Neurological Disorders - Drug Targets Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Early Features in Frontotemporal Dementia
Current Alzheimer Research Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design